CombiMatrix Enters into Distribution Agreement with Singapore-Based Cell Sciences; Cell Sciences to Distribute Arrays Including CombiMatrix's New Influenza Array
"We are very pleased to have expanded our distribution network into South East Asia," said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix. "I am confident that by joining forces with Cell Sciences, we can accelerate sales growth and enhance our collective market share."
“Cell Sciences has identified CombiMatrix's platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology”
"Cell Sciences has identified CombiMatrix's platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology," said Dr. John Khong, Vice President & General Manager, Cell Sciences. "This has a huge market potential in the Asia Pacific region and we look forward to a long and fruitful relationship. In addition, we are impressed with CombiMatrix's recently launched influenza array. As we enter the flu season, and focus on H5N1 intensifies, we anticipate increased interest in this array."
ABOUT CELL SCIENCES
Cell Sciences is a subsidiary of CyGenics which is listed in the Australian Stock Exchange (ASX). It has an established network covering Singapore, Malaysia, Thailand, Indonesia, Philippines, Hong Kong, China, Australia and USA. Cell Sciences is a supplier of diagnostics for life science research and manufactures proprietary products. Cell Sciences drives the sales, marketing and distribution for biomedical products. In Jan 2004, the company launched a patented 3-D growth scaffold and the market's first disposable cell culture spinner systems.
Cell Sciences markets products targeting an extensive customer base comprising laboratories (research, clinical and bioprocessing), industry (biopharmaceuticals), specialists and hospitals. The company focuses on product lines core to the strategic business of the CyGenics Group in areas of stem cell biotechnology and regenerative medicines, as well as products that add to a more comprehensive offering to the customers we serve. Visit us at www.cygenics.com/cellsciences.
CyGenics is a cell therapy company focused on the development and commercialization of adult stem cell-related technologies and applications into therapeutic products and services. From its headquarters in Australia, CyGenics operates four subsidiary businesses: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), Cytomatrix (cell therapeutics and technology development) based in the USA, and CytoVations (new product development) also based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 34 patent portfolios, which include over 130 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, high resolution optics, image resolution enhancement, interactive data sharing, interactive television, hearing aid ECS, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.
Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.